Title:
BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/224656
Kind Code:
A1
Abstract:
Provided are a substituted dihydropyrazole compound as shown in formula I, which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, wherein the definition of each group in the formula is detailed in the description. In addition, also disclosed are a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.
Inventors:
ZHOU FUSHENG (CN)
XU XIAOMING (CN)
ZHANG LEITAO (CN)
JIANG TAO (CN)
LIU YINGTAO (CN)
LAN JIONG (CN)
XU XIAOMING (CN)
ZHANG LEITAO (CN)
JIANG TAO (CN)
LIU YINGTAO (CN)
LAN JIONG (CN)
Application Number:
PCT/CN2020/089328
Publication Date:
November 12, 2020
Filing Date:
May 09, 2020
Export Citation:
Assignee:
GENFLEET THERAPEUTICS SHANGHAI INC (CN)
ZHEJIANG GENFLEET THERAPEUTICS CO LTD (CN)
ZHEJIANG GENFLEET THERAPEUTICS CO LTD (CN)
International Classes:
C07D231/06; A61K31/4155; A61P35/00; A61P37/00
Domestic Patent References:
| WO2019224773A1 | 2019-11-28 | |||
| WO2016185423A1 | 2016-11-24 | |||
| WO2008079277A1 | 2008-07-03 | |||
| WO2018092089A1 | 2018-05-24 | |||
| WO2018154520A1 | 2018-08-30 |
Other References:
HARRIS, P.A. ET AL.: "Discovery and Lead-Optimization of 4, 5-Dihydropyrazoles as Mono- Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase", J. MED. CHEM., vol. 62, 23 April 2019 (2019-04-23), pages 5096 - 5110, XP055616358, DOI: 10.1021/acs.jmedchem.9b00318
Attorney, Agent or Firm:
SHANGHAI GOOIP CO., LTD. (CN)
Download PDF: